Klinikum Chemnitz gGmbH
Klinikum Chemnitz gGmbH
Chemnitz, Germany12 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy | CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, lymphoma, malignant histiocytosis, neoplasm, skin disorder, skin neoplasm | Recruiting | Not stated | 2026-09-15 | NCT07785180 | |
| Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer | HER2-positive Breast Cancer | Recruiting | Phase 2 | 2026-09-11 | NCT05306041 | |
| Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation | acute myeloid leukemia, myelodysplastic syndrome | Recruiting | Phase 2 | 2026-08-26 | NCT06717958 | |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2026-08-10 | NCT06731478 | |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-08-06 | NCT05232916 | |
| GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Not stated | 2026-08-05 | NCT02872987 | |
| Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-07-14 | NCT02864992 | |
| Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection | VEXAS syndrome | Recruiting | Not stated | 2026-05-15 | NCT06377462 | |
| REDUCE LAP-HF III Corvia Protocol 1701 | cardiovascular disorder, heart disorder, heart failure | Active, not recruiting | Not stated | 2026-05-12 | NCT03191656 | |
| Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma | neoplasm | Recruiting | Phase 3 | 2026-02-05 | NCT07270991 | |
| Pre-Operative Treatment in REseCTable COlon CanceR | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colon carcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, malignant colon neoplasm, neoplasm | Not yet recruiting | Phase 3 | 2025-03-28 | NCT06899477 | |
| Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients | primary central nervous system lymphoma | Recruiting | Phase 3 | 2025-02-17 | NCT06830421 |